ArticleNature communications2017
Topical tacrolimus for the treatment of secondary lymphedema.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Malar Bags After Lower Lid Blepharoplasty and Facelift: A Randomized Controlled Trial of the Effects of Tacrolimus
Tacrolimus as Treatment of Breast Cancer-Related Lymphedema
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Current Advancements in Animal Models of Postsurgical Lymphedema: A Systematic Review.Advances in wound care · 2022Pooled it
- Trial
- Time-Dependent Efficacy of Lymphaticovenous Anastomosis in Secondary Lymphedema: A Rabbit Model Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Review
- Keratinocytes: A key player in skin immunity and their emerging roles in secondary lymphedema.JID innovations : skin science from molecules to population health · 2026Review
- Critical role of keratinocytes and protease-activated receptor 2 in secondary lymphedema development.Clinical and translational medicine · 2026Article
- Macrophages recruited by implanted fibrin gels promote regeneration of injured lymphatic vessels.Scientific reports · 2026Article
- Immune cell fibrotic plasticity: mesenchymal-like reprogramming of macrophages, neutrophils and T cells.Frontiers in immunology · 2026Review
- Comprehensive overview of management and risk assessment of breast cancer-related lymphedema: a multidisciplinary approach.Frontiers in oncology · 2026Review
- Mechanisms and treatments of lymphedema.Frontiers in immunology · 2026Review
- Article
- Article
- Epigenetic reprogramming via EZH2 inhibition rescues fibroadipose pathogenesis in secondary lymphedema through activating PPARγ signaling.Journal of orthopaedic translation · 2025Article
- The Usefulness of Indocyanine Green in Modern Gynecological Oncology-Analysis, Literature Review, and Future Perspectives.Cancers · 2025Review
- Article
- [Research progress on rodent models of secondary lymphedema].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025Review
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema.Microcirculation (New York, N.Y. : 1994) · 2025Review
- Article
- Advances in etiology, pathophysiology, diagnosis, and management of lymphedema: a comprehensive review.Frontiers in medicine · 2025Review
- Grape seed proanthocyanidins improve lymphatic drainage and blood perfusion in secondary lymphedema models.Frontiers in oncology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Secondary lymphedema, a life-long complication of cancer treatment, currently has no cure. Lymphedema patients have decreased quality of life and recurrent infections with treatments limited to palliative measures. Accumulating evidence indicates that T cells play a key role in the pathology of lymphedema by promoting tissue fibrosis and inhibiting lymphangiogenesis. Here using mouse models, we show that topical therapy with tacrolimus, an anti-T-cell immunosuppressive drug, is highly effective in preventing lymphedema development and treating established lymphedema. This intervention markedly decreases swelling, T-cell infiltration and tissue fibrosis while significantly increasing formation of lymphatic collaterals with minimal systemic absorption. Animals treated with tacrolimus have markedly improved lymphatic function with increased collecting vessel contraction frequency and decreased dermal backflow. These results have profound implications for lymphedema treatment as topical tacrolimus is FDA-approved for other chronic skin conditions and has an established record of safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.